Vaccine Development

Jul 17, 2017
By BioPharm International Editors
GSK plans to deliver up to 40 million doses of its quadrivalent flu vaccine for the 2017–2018 season.
Jul 11, 2017
By BioPharm International Editors
The acquisition will add recombinant-based influenza vaccine to Sanofi Pasteur’s portfolio
Jul 10, 2017
By BioPharm International Editors
The National Institutes of Health says a new study showed that hydroxychloroquine reduced the transmission of Zika in pregnant mice.
Jun 28, 2017
By BioPharm International Editors
Two recently-signed agreements will transfer Takeda’s measles and acellular pertussis vaccine technologies to India-based multinational company Biological E. Limited to develop low-cost combination vaccines including diphtheria, tetanus and acellular pertussis (DTaP), and measles-rubella (MR) vaccines.
Jun 22, 2017
By BioPharm International Editors
A loan from the European Investment Bank will give BiondVax resources for Phase III trials and a manufacturing facility for its universal flu vaccine.
Jun 21, 2017
By BioPharm International Editors
The company successfully produced cell-based influenza vaccines at a commercial scale in its facility in NC.
Apr 12, 2017
By BioPharm International Editors
The agency issued its recommendation for the influenza virus strains European vaccine manufacturers should include for 2017.
Apr 11, 2017
By BioPharm International Editors
In a new study, researchers from Boston Children’s Hospital study responses to pneumococcal vaccine in infant monkeys.
Jan 04, 2017
By BioPharm International Editors
Prokarium in the UK and Probiomed in Mexico hope to demonstrate large-scale production of oral vaccines that will reduce cost compared to injections and improve availability.
Dec 16, 2016
By BioPharm International Editors
Univercells received a grant from the Bill & Melinda Gates Foundation for the development of a vaccine manufacturing platform.
native1_300x100
lorem ipsum